Emergingby GlyphCalico licenses Mabwell's IL-11 antibody for age-related disease
Calico gained exclusive rights to IL-11 directed therapeutics including the Phase 1 antibody 9MW3811.
Longevity biotechcalicolabs.com
Mabwell Bioscience
Public companyCN1 field
Where it works
| Technology | ||
|---|---|---|
| Longevity biotechDeveloped the IL-11 antibody 9MW3811, explored for age-related diseases and licensed to Calico. | Developed the IL-11 antibody 9MW3811, explored for age-related diseases and licensed to Calico. | calicolabs.com |
Events
About
- Source
- calicolabs.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Oct 6, 2026
- Across Glyph
- Mabwell Bioscience on Companies
Mabwell Bioscience
Joined in Longevity biotech. Developed the IL-11 antibody 9MW3811, explored for age-related diseases and licensed to Calico.
Mabwell Bioscience
Added in Longevity biotech. Developed the IL-11 antibody 9MW3811, explored for age-related diseases and licensed to Calico.